Search Results - "Koneva, O A"

Safety and Tolerability of Rituximab in the Treatment of Systemic Sclerosis by Garzanova, L. A., Ananyeva, L. P., Koneva, O. A., Desinova, O. V., Starovoytova, M. N., Ovsyannikova, O. B., Shayakhmetova, R. U., Glukhova, S. I.

“…Rituximab (RTX) has been used for the treatment of systemic sclerosis (SSс) for a long time and has shown good efficacy for skin fibrosis and interstitial lung…”
Get full text

The Use of “Acellbia”—A Biosimilar of Rituximab in Systemic Sclerosis by Ananyeva, L. P., Garzanova, L. A., Desinova, O. V., Shayakhmetova, R. U., Starovoitova, M. N., Koneva, O. A., Ovsyannikova, O. B., Glukhova, S. I., Nasonov, E. L.

“…The possibilities of modern therapy for systemic sclerosis (SSc) remains limited, since most of the used drugs do not have a disease-modifying effect. This…”
Get full text

Erratum to: Anti-topoisomerase 1 Antibody Level Changes after B Cell Depletion Therapy in Systemic Sclerosis by Ananyeva, L. P., Garzanova, L. A., Koneva, O. A., Starovoytova, M. N., Desinova, O. V., Ovsyannikova, O. B., Shayakhmetova, R. U., Cherkasova, M. V., Aleksankin, A. P., Nasonov, E. L.

“…An Erratum to this paper has been published: https://doi.org/10.1134/S1607672923050022…”
Get full text

Anti-topoisomerase 1 Antibody Level Changes after B Cell Depletion Therapy in Systemic Sclerosis by Ananyeva, L. P., Garzanova, L. A., Koneva, O. A., Starovoytova, M. N., Desinova, O. V., Ovsyannikova, O. B., Shayakhmetova, R. U., Cherkasova, M. V., Aleksankin, A. P., Nasonov, E. L.

“…The aim of our study was to assess the relationship between the changes of antinuclear autoantibodies (ANAs) and autoantibodies to topoisomerase 1 (anti-Topo…”
Get full text

Renal function during long-term therapy with rituximab in patients with systemic sclerosis by Starovoitova, M. N., Desinova, O. V., Ananyeva, L. P., Koneva, O. A., Garzanova, L. A., Ovsyannikova, O. B., Shayakhmetova, R. U.

“…   In systemic sclersis (SSc), different types of renal involvement occur. Their severity can range from asymptomatic deterioration of renal function to…”
Get full text

The use of “Acellbia” – a biosimilar of rituximab in systemic sclerosis by Ananyeva, L. P., Garzanova, L. A., Desinova, O. V., Shayakhmetova, R. U., Starovoytova, M. N., Koneva, O. A., Ovsyannikova, O. B., Glukhova, S. I., Nasonov, E. L.

“…Introduction. The possibilities of modern therapy for systemic sclerosis (SSc) remains limited, since most of the used drugs do not have a diseasemodifying…”
Get full text

Ovarian reserve in patients with systemic sclerosis by Goloeva, R. G., Ananyeva, L. P., Alekberova, Z. S., Glukhova, S. I., Cherkasova, M. V., Garzanova, L. A., Koneva, O. A., Reshetnyak, T. M.

“…Objective . To evaluate the ovarian reserve in women with systemic sclerosis (SSc) and to analyze the relationship of the concentration of anti-Müllerian…”
Get full text

Safety and tolerability of rituximab in the treatment of systemic sclerosis by Garzanova, L. A., Ananyeva, L. P., Koneva, O. A., Desinova, O. V., Starovoytova, M. N., Ovsyannikova, O. B., Shayakhmetova, R. U., Glukhova, S. I.

“…Introduction. Rituximab (RTX) has been used for the treatment of systemic sclerosis (SSс) for a long time and has shown good efficacy for skin fibrosis and…”
Get full text

Relationship between digital ulcers and severity of lung function test in systemic sclerosis over a five-year period by Ovsyannikova, O. B., Koneva, O. A., Ananieva, L. P., Garzanova, L. A., Srarovoytova, M. N., Desinova, O. V., Shayakhmetova, R. U.

“…Background . Systemic sclerosis-related interstitial lung disease (SSc-ILD) is the leading cause of death in SSc. Predictors of the outcomes of ILD in SSc are…”
Get full text

Interstitial lung disease in systemic sclerosis (systemic scleroderma) by Ananyeva, L. P., Tyurin, I. E., Koneva, O. A., Garzanova, L. A., Lila, A. M.

“…In systemic sclerosis (SSc), interstitial lung disease (ILD) is common (>80%) and worsens the prognosis of the disease, but severe progressive damage develops…”
Get full text

Anti-topoisomerase 1 antibody level changes after B сell depletion therapy in systemic sclerosis by Ananyeva, L. P., Garzanova, L. A., Koneva, O. A., Starovoytova, M. N., Desinova, O. V., Ovsyannikova, O. B., Shayakhmetova, R. U., Cherkasova, M. V., Aleksankin, A. P., Nasonov, E. L.

“…The aim of our study was to assess the relationship between the changes of antinuclear autoantibodies (ANA) and autoantibodies to topoisomerase 1 (anti-Topo 1)…”
Get full text

THE IMPORTANCE OF HIGH-RESOLUTION COMPUTED TOMOGRAPHY IN EVALUATING THE EFFICACY OF RITUXIMAB IN PATIENTS WITH INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS by O. A. Koneva, O. V. Desinova, L. P. Ananyeva, N. V. Kovaleva

“…Multi-slice spiral computed tomography (MSCT) of the chest is the gold standard for confirming interstitial changes in the lung; but the role of this technique…”
Get full text

Effect of rituximab on heart involvement in systemic sclerosis by Garzanova, L. A., Ananyeva, L. P., Koneva, O. A., Ovsyannikova, O. B.

“…As of now, there has been a great body of data on the use of rituximab (RTM) in systemic sclerosis (SS), mainly on its positive effect on skin fibrosis and…”
Get full text

Autologous hematopoietic stem cell transplantation in the treatment of systemic sclerosis. Part 2. Safety and complications by Ovsyannikova, O. B., Ananyeva, L. P., Koneva, O. A., Garzanova, L. A., Desinova, O. V., Shayakhmetova, R. U., Starovoitova, M. N., Lila, A. M.

“…Autologous hematopoietic stem cell transplantation (auto-HSCT) is presently the only disease-modifying strategy for the treatment of systemic sclerosis (SSs)…”
Get full text

Autologous hematopoietic stem cell transplantation in the treatment of systemic sclerosis. Part 1. Clinical aspects by Ovsyannikova, O. B., Ananyeva, L. P., Koneva, O. A., Garzanova, L. A., Shayakhmetova, R. U., Desinova, O. V., Starovoitova, M. N., Lila, A. M.

“…Diffuse cutaneous systemic sclerosis (SSc) characterized by an acute, rapidly progressive course and severe damage to the internal organs has an unfavorable…”
Get full text

Short-term absolute B-cell counts monitoring in systemic sclerosis patients treated with rituximab by Ananieva, L. P., Garzanova, L. A., Desinova, O. V., Koneva, O. A., Starovoytova, M. N., Ovsyannikova, O. B., Aleksankn, A. P., Glukhova, S. I.

“…Objective . To evaluate B-cell counts in circulation of SS patients prior to initiation and one year after completion of RTM therapy. Subjects and methods …”
Get full text

The resolution of the Expert Council on Interstitial Lung Diseases in Systemic Scleroderma (Moscow, October 14, 2019) by Avdeev, S. N., Ananyeva, L. P., Zhilyaev, E. V., Zonova, E. V., Klimenko, A. A., Koneva, O. A., Lila, A. M., Pershina, E. S., Stremoukhov, A. A., Terpigorev, S. A., Tyurin, I. E., Shostak, N. A.

“…The conclusion of the Expert Council presents the results of discussing the diagnosis and therapy of interstitial lung diseases in systemic scleroderma. The…”
Get full text

Clinical and laboratory characteristics of patients with systemic sclerosis positive for anti-ribonucleoprotein antibodies by Shayakhmetova, R. U., Ananyeva, L. P., Koneva, O. A., Starovoitova, M. N., Desinova, O. V., Ovsyannikova, O. B., Garzanova, L. A.

“…Among the patients fulfilling the criteria for systemic sclerosis (SS), there is a subgroup without SS-specific antinuclear antibodies, but positive for…”
Get full text

Immunological features in anti-U1-ribonucleoprotein antibody positive patients with systemic scleroderma by Shayakhmetova, R. U., Ananyeva, L. P., Koneva, O. A., Starovoitova, M. N, Desinova, O. V., Ovsyannikova, O. B., Garzanova, L. A.

“…In anti-U1-ribonucleoprotein (anti-U1-RNP) antibody positive patients with systemic scleroderma (SSD), the clinical picture and course of the disease have…”
Get full text

Comparative characteristics of the main phenotypes of systemic sclerosis by Shayakhmetova, R. U., Ananyeva, L. P., Starovoitova, M. N., Desinova, O. V., Koneva, O. A., Ovsyannikova, O. B., Garzanova, L. A., Cherkasova, M. V., Alekperov, R. T.

“…Various clinical and immunological phenotypes of systemic sclerosis (SS) differ in the frequency and severity of manifestations of the disease, the progression…”
Get full text